Page last updated: 2024-08-21

oxazoles and Sarcoma

oxazoles has been researched along with Sarcoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Ameratunga, M; Aspegren, J; Bono, P; Braña, I; de Bono, JS; Korjamo, T; Plummer, R; Postel-Vinay, S; Snapir, A	1
Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y	1

Trials

1 trial(s) available for oxazoles and Sarcoma

Article	Year
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. British journal of cancer, 2020, Volume: 123, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Biological Availability; Blood Platelets; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Fatigue; Female; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Oxazoles; Prostatic Neoplasms, Castration-Resistant; Proteins; Pyridines; Quinolines; Sarcoma; Small Cell Lung Carcinoma; Young Adult	2020

Article

Year

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.

British journal of cancer, 2020, Volume: 123, Issue:12

Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Biological Availability; Blood Platelets; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Fatigue; Female; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Oxazoles; Prostatic Neoplasms, Castration-Resistant; Proteins; Pyridines; Quinolines; Sarcoma; Small Cell Lung Carcinoma; Young Adult

2020

Other Studies

1 other study(ies) available for oxazoles and Sarcoma

Article	Year
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude. Toxicologic pathology, 2012, Volume: 40, Issue:5 Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1	2012

Article

Year

The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.

Toxicologic pathology, 2012, Volume: 40, Issue:5

Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1

2012